Statins in the primary prevention of cardiovascular disease (Q38111961)

29 August 2017

title

Statins in the primary prevention of cardiovascular disease (English)

1 reference

29 August 2017

main subject

cardiovascular disease

1 reference

1

Željko Reiner

1 reference

29 August 2017

language of work or name

English

0 references

publication date

4 June 2013

1 reference

Nature Reviews Cardiology

29 August 2017

published in

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

8

1 reference

29 August 2017

page(s)

453-464

1 reference

The burden of hyperlipidaemia and diabetes in cardiovascular diseases

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Dyslipidemias in the prevention of cardiovascular disease: risks and causality.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Cholesterol reduction yields clinical benefits: meta-analysis including recent trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Guidelines, position papers and critical reviews: differences and similarities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Guidelines on CVD prevention: confusing or complementary?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacolo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Drug therapy in the heart transplant recipient: part IV: drug-drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Long-term follow-up of the West of Scotland Coronary Prevention Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

The JUPITER trial: myth or reality?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Lipid lowering for primary prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins for the primary prevention of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins for people at low risk of cardiovascular disease – Authors' reply

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Risks associated with statin therapy: a systematic overview of randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Lipid-modifying therapies and risk of pancreatitis: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Effects of lovastatin on cognitive function and psychological well-being

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and cancer risk: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and cancer: a meta-analysis of case-control studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins are associated with a reduced risk of gastric cancer: a population-based case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Common cancer risk and statins: a population-based case-control study in a Chinese population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins, low-density lipoprotein cholesterol, and risk of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin use and risk of bladder cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and the risk of lung cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin use and the risk of esophageal cancer: a population-based case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin use and reduced cancer-related mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Suboptimal management of cardiovascular risk factors in coronary heart disease patients in primary care occurs particularly in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Meta-analysis of statin effects in women versus men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastati

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Time Trends in the Use of Cholesterol-Lowering Agents in Older Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Low prevalence of lipid lowering drug use in older men with established coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and the risk of lung, breast, and colorectal cancer in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Early statin therapy restores endothelial function in children with familial hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin treatment in children with familial hypercholesterolemia: the younger, the better

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Lipid levels and the risk of ischemic stroke in women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

High-dose atorvastatin after stroke or transient ischemic attack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins and intracerebral hemorrhage: a retrospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin prescription in men and women at cardiovascular risk: to whom and when?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

First-line drugs for hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statins for Cardiovascular Prevention According to Different Strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Primary prevention of coronary heart disease with statins: it's not about the money

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2013.80

Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data

31 March 2020

1 reference

12 December 2020

Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis

1 reference

12 December 2020

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement

1 reference

12 December 2020

Statins for secondary cardiovascular disease prevention for older primary care patients

1 reference

12 December 2020

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

12 December 2020

Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada

1 reference

12 December 2020

Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2013.80

1 reference

29 August 2017

1 reference